Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Clearside Biomedical develops innovative ophthalmic therapies and delivery platforms, primarily utilizing its proprietary suprachoroidal space injection technology. Its core product, XIPERE, treats macular edema associated with uveitis. The company partners globally for development and commercialization, leveraging its SCS Microinjector for targeted, non-surgical drug delivery to the back of the eye, aiming to improve efficacy, safety, and patient access in retinal and choroidal diseases.
This description was generated via AI from an annual report. Updated about 1 year ago.